The Story of Ruxolitinib: The First Approved Topical JAK Inhibitor for Atopic Dermatitis
Time: 10:15 am
day: Day One
Details:
- The story from discovery to clinical development for a moderate to severe
inflammatory skin indication - Inspecting the JAK/STAT pathways critical to Incyte’s JAK inhibitor portfolio
- Reviewing the commercialization and market strategy of a ‘twice daily’ applied
topical cream
